Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer

Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues.

from Reuters: Health News https://ift.tt/2QhhH1f
via IFTTT